Previous close | 27.78 |
Open | 27.71 |
Bid | 27.78 x 1000 |
Ask | 27.82 x 2900 |
Day's range | 27.79 - 27.93 |
52-week range | 25.61 - 42.22 |
Volume | |
Avg. volume | 43,665,659 |
Market cap | 157.673B |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 75.26 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.68 (6.05%) |
Ex-dividend date | 25 Jan 2024 |
1y target est | N/A |
Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic. Is PFE stock a sell?
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.